The research presented in Drug Delivery to the Lungs (DDL) 2020 showed a new actuator that offers inhaler users real-time input.
FREMONT, CA: The research discussed at the big conference on respiratory health, Drug Delivery to the Lungs (DDL) 2020, showed that a new form of actuator that offers inhaler users real-time input on its technique could be incorporated into a pMDI inhaler without compromising the distribution of aerosol particle size (APSD) or dose delivery. It is a crucial step towards the mass production of low-cost smart inhalers, as at the manufacturing level, the latest actuator could be incorporated into inhalers.
When the inhaler is utilized correctly, the In-Tone actuator, produced by leading UK medical technology manufacturer Clement Clarke International, has an acoustic signal that directs the user as to whether they are using the correct inhaler technique. The acoustic signal can also be identified by a companion mobile app that provides the inhaler patient with visual input and tips and maintains a record of inhaler usage that can be shared with the clinical team of the user.
The research presented at the DDL conference explored whether the position of the acoustic function within the actuator will affect the efficient delivery of drugs for current and future HFC152a-based formulations. This propellant has a reduced effect on global warming. The study found that the APSD profile or main variables of the Ventolin Evohaler or the HFC152a trial formulation were not affected by In-Tone.
The lead author of the study, Mark Sanders, Chief Technology Officer at Clement Clarke International, comments, “The data from our study suggest that the In-Tone guidance actuator can deliver the required APSD performance with todays and future formulations. This is a major step forwards towards the possibility of manufacturing low-cost, non-Bluetooth smart inhalers capable of providing user guidance, which could lead to improved inhaler technique and work alongside greener formulations. This technology really is a viable alternative to the expensive Bluetooth smart inhalers, which to date have failed to penetrate the mass market.”